This product consists of a pooled S9 fraction prepared from liver tissues of 50 donors diagnosed with non-alcoholic steatohepatitis (NASH), providing a robust and clinically relevant model for studying drug metabolism and toxicity in the context of liver disease. The S9 fraction contains both cytosolic and microsomal enzymes, enabling comprehensive evaluation of phase I and phase II metabolic pathways.
 
Ideal for use in preclinical drug development, DMPK studies, and toxicity screening, this NASH-specific S9 pool allows for better prediction of metabolic profiles and drug behavior in diseased hepatic environments. Quality-controlled for enzymatic activity and protein concentration, ensuring reproducible and reliable results.